推荐产品
等级
pharmaceutical primary standard
API类
nifedipine
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC
InChI
1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
InChI key
HYIMSNHJOBLJNT-UHFFFAOYSA-N
基因信息
human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)
正在寻找类似产品? 访问 产品对比指南
应用
Nifedipine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Nifedipine Capsules
- Nifedipine Extended-Release Tablets
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
预防措施声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
P D Henry
The American journal of cardiology, 46(6), 1047-1058 (1980-12-01)
Calcium antagonists (slow channel blocking agents) are a very heterogeneous group of agents with dissimilar structural, electrophysiologic and pharmacologic properties. Nifedipine is a potent, long-acting vasodilator that has proved highly efficacious in relieving anginal symptoms caused by coronary vasospasm. In
P D Henry et al.
The Journal of clinical investigation, 68(5), 1366-1369 (1981-11-01)
We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions
Stability studies on nifedipine tablets using thermogravimetry and differential scanning calorimetry.
Franco, P. I. B. M., E. C. Conceic?o, and M. I. G. Leles.
Journal of Thermal Analysis and Calorimetry, 93.2, 381-385 (2008)
Ryuichi Morishita et al.
Drugs, 66 Spec No 1, 31-33 (2008-01-19)
Useful drug therapy for inhibiting the extension of an aortic aneurysm or promoting its involution has not yet been established. Hypertension is a known risk factor for extension of an aortic aneurysm. However, on a cellular level it is believed
Norio Taira
Drugs, 66 Spec No 1, 1-3 (2008-01-19)
Nifedipine was synthesized by Bayer Germany in 1966 and considered for clinical use as a coronary vasodilator in patients with angina pectoris. Japanese investigators played a great part in the pre-clinical and clinical development of nifedipine. Professor Hashimoto demonstrated that
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门